Asahi Kasei Therapeutics Begins AIC468 Phase 2a Trial in Kidney Transplant Recipients

Asahi Kasei Therapeutics, Inc., the global specialty pharmaceutical business of Tokyo-based Asahi Kasei, recently announced that the first patient has been dosed in a randomized Phase 2a clinical trial (NCT07503561) evaluating AIC468, a novel antiviral antisense oligonucleotide (ASO), in adult kidney transplant recipients with BK virus (BKV) infection. The investigational program was developed by Aicuris […]